SCM
RARE icon

Stonepine Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Stonepine Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$2.3M – 97
2025
Q4 		$2.3M Buy
+100,000
New +$3.29M 1.68% 20

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Stonepine Capital Management's RARE Position: Q4 2025 in Review

Stonepine Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2025, closing a stake of 20,000 shares — an estimated $658K sold.

Stonepine Capital Management first reported a position in RARE in Q3 2025 and held it in 1 quarter. The position peaked at $602K in Q3 2025. 287 funds tracked by Wall St. Rank hold RARE as of Q4 2025.

  • Stonepine Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Stonepine Capital Management sold 20,000 Ultragenyx Pharmaceutical shares in Q4 2025, an estimated $658K.
  • Stonepine Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2025 and held it in 1 quarter.
  • Stonepine Capital Management's Ultragenyx Pharmaceutical position peaked at $602K in Q3 2025.
  • 287 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2025.

Based on Stonepine Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.